SCHEMBL21114767

SCHEMBL21114767

Brc1ccc2nc(N3CCOCC3)sc2c1

nearest known ligand 0.76

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 14/20 0.76
NPC1 O15118 13/20 0.76
MAPT P10636 7/20 0.76
HTT P42858 4/20 0.76
ALDH1A1 P00352 3/20 0.76
SMN1; SMN2 Q16637 9/20 0.71
GAA P10253 2/20 0.70
AR P10275 1/20 0.70
TP53 P04637 3/20 0.59
USP2 O75604 1/20 0.59
PKM P14618 1/20 0.59
HPGD P15428 2/20 0.58
TSHR P16473 2/20 0.58
ALOX15 P16050 2/20 0.58
HSD17B10 Q99714 1/20 0.58
LRRK2 Q5S007 1/20 0.56
STAT3 P40763 1/20 0.54
CLK1 P49759 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14810634 0.88 RAB9A (0.64) RAB9ANPC1MAPTHTTALDH1A1
SCHEMBL21154647 0.82 RAB9A (0.70) RAB9ANPC1MAPTHTTALDH1A1
SCHEMBL31349393 0.82 RAB9A (1.00) RAB9ANPC1MAPTHTTALDH1A1
SCHEMBL21154016 0.82 RAB9A (0.74) RAB9ANPC1MAPTHTTALDH1A1
SCHEMBL1656308 0.82 AR (1.00) RAB9ANPC1MAPTHTTALDH1A1
SCHEMBL14824499 0.82 RAB9A (1.00) RAB9ANPC1MAPTHTTALDH1A1
SCHEMBL1656708 0.82 RAB9A (0.70) RAB9ANPC1MAPTHTTALDH1A1
SCHEMBL14852353 0.82 RAB9A (0.76) RAB9ANPC1MAPTHTTALDH1A1
SCHEMBL1981263 0.82 RAB9A (0.76) RAB9ANPC1MAPTHTTALDH1A1
SCHEMBL9963514 0.81 RAB9A (0.74) RAB9ANPC1MAPTHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3735411-B1 1,3,4,5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER`S DISEASE AC IMMUNE SA (CH) 2024-07-10 EP disclosed
EP-3735411-B1 1,3,4,5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER`S DISEASE AC IMMUNE SA (CH) 2024-07-10 EP disclosed
US-11814378-B2 Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates AC IMMUNE SA (CH) 2023-11-14 US disclosed
US-11814378-B2 Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates AC IMMUNE SA (CH) 2023-11-14 US disclosed
CN-111757882-B Compounds for treating, alleviating or preventing conditions associated with tau aggregates AC免疫有限公司 2023-08-22 CN disclosed
EP-3735411-A1 1, 3, 4, 5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER'S DISEASE AC Immune SA (CH) 2020-11-11 EP disclosed
CN-111757882-A 1,3,4, 5-tetrahydro-2H-pyrido [4,3-b ] indole derivatives for the treatment, alleviation or prevention of disorders associated with Tau aggregates such as alzheimer's disease AC免疫有限公司 2020-10-09 CN disclosed
US-20200148679-A1 Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates AC IMMUNE SA (CH) 2020-05-14 US disclosed
US-10633383-B2 Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates AC IMMUNE SA (CH) 2020-04-28 US disclosed
US-20190211012-A1 Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates AC IMMUNE SA (CH) 2019-07-11 US disclosed
WO-2019134978-A1 1, 3, 4, 5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER'S DISEASE AC IMMUNE SA (CH) 2019-07-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190211012-A1 Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates MAPT, MAP1LC3A, MAP1LC3B RAB9A 1905/4885NPC1 290/4885MAPT 1/4885
US-10633383-B2 Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates MAPT, MAP1LC3A, TUBB3 RAB9A 2189/4885NPC1 325/4885MAPT 1/4885
US-20200148679-A1 Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates MAPT, MAP1LC3A, MAP1LC3B RAB9A 1905/4885NPC1 290/4885MAPT 1/4885
US-11814378-B2 Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates MAPT, MAP1LC3A, TUBB3 RAB9A 2189/4885NPC1 325/4885MAPT 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.